Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncolo
Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approachIpsen to pay Marengo $45 million upfront with potential for additional milestone paymentsPARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:Ipsen (...